Top

Published in:

01-04-2021 | Probiotics | Original Article

Intestinal microbiome: a new target for chalaziosis treatment in children?

Authors: Mariaelena Filippelli, Roberto dell’Omo, Angela Amoruso, Ilaria Paiano, Marco Pane, Pasquale Napolitano, Silvia Bartollino, Ciro Costagliola

Published in: European Journal of Pediatrics | Issue 4/2021

Abstract

Intestinal dysbiosis (changes in the gut commensal microbiome) is related to several ophthalmic diseases. The aim of this study was to verify whether oral specific probiotics can alter the clinical course of chalaziosis and its recurrence. A prospective comparative pilot study involving 26 children suffering from chalaziosis was conducted. Children were randomly divided into two groups. The first group received medical treatment (lid hygiene, warm compression and dexamethasone/tobramycin ointment for at least 20 days), and the second group received medical treatment plus a daily supplementation of oral probiotics (≥ 1 × 10^9 live cells of Streptococcus thermophilus ST10 (DSM 25246), ≥ 1 × 10^9 live cells of Lactococcus lactis LCC02 (DSM 29536) and ≥ 1 × 10^9 live cells of Lactobacillus delbrueckii subsp. bulgaricus (DSM 16606) with maltodextrin as the bulking agent (Probiotical S.p.A., Novara, Italy). All patients were evaluated at 2-week intervals for 3 months. If the lesion had not disappeared or decreased in size to 1 mm or less in diameter at the time of subsequent visits, the same procedure was repeated for another 3-month cycle. There was a significant difference in the time taken for complete resolution of the chalazion between the two groups in favour of the children receiving the probiotics. The treatment was not associated with any significant complications in either group. Trial registration: The trial was registered at clinical trials.gov under NCT04322500 on 25/03/2020 (“retrospectively registered”).

Conclusions: Modification of the intestinal microbiome with specific probiotics can alter the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis. Probiotic supplementation can increase the effectiveness of traditional therapies by prompting the complete resolution of chalaziosis in a shorter amount of time, in an easy and feasible way.

What is Known: • The intestinal microbiome plays a crucial role in several inflammatory diseases of the eye and is considered a therapeutic target. • Probiotics play a role in the prevention and treatment of different conditions in children.
What is New: • In children probiotic supplementation is safe and effective. • Probiotic supplementation reduced the time required for complete resolution of the chalazion.

George Kerry R, Patra JK, Gouda S, Park Y, Shin HS, Das G (2018) Benefaction of probiotics for human health: a review. J Food Drug Anal 26(3):927–939. https://doi.org/10.1016/j.jfda.2018.01.002CrossRefPubMed

Food and Agriculture Organization and World Health Organization Expert Consultation (2001) Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Córdoba, Argentina: Food and Agriculture Organization of the United Nations and World Health Organization. Available from:.http://www.fao.org/3/a-a0512e.pdf Accessed: 29 March 2020

McLean MH, Dieguez D Jr, Miller LM, Young HA (2015) Does the microbiota play a role in the pathogenesis of autoimmune diseases? Gut. 64(2):332–341. https://doi.org/10.1136/gutjnl-2014-308514CrossRefPubMed

Scher JU, Littman DR, Abramson SB (2016) Microbiome in inflammatory arthritis and human rheumatic diseases. Arthritis Rheum 68(1):35–45. https://doi.org/10.1002/art.39259CrossRef

Ochoa-Reparaz J, Kasper LH (2017) The influence of gut-derived CD39 regulatory T cells in CNS demyelinating disease. Transl Res 179:126–138. https://doi.org/10.1016/j.trsl.2016.07.016CrossRefPubMed

Kalyana Chakravarthy S, Jayasudha R, Sai Prashanthi G, Ali MH, Sharma S, Tyagi M, Shivaji S (2018) Dysbiosis in the gut bacterial microbiome of patients with uveitis, an inflammatory disease of the eye. Indian J Microbiol 58(4):457–469. https://doi.org/10.1007/s12088-018-0746-9CrossRefPubMedPubMedCentral

Iovieno A, Lambiase A, Sacchetti M, Stampachiacchiere B, Micera A, Bonini S (2008) Preliminary evidence of the efficacy of probiotic eye-drop treatment in patients with vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol 246(3):435–441. https://doi.org/10.1007/s00417-007-0682-6CrossRefPubMed

Tavakoli A, Flanagan JL (2019) The case for a more holistic approach to dry eye disease: is it time to move beyond antibiotics? Antibiotics (Basel) 8(3):E88. https://doi.org/10.3390/antibiotics8030088CrossRef

Lin P (2018) The role of intestinal microbiome in ocular inflammatory disease. Curr Opin Ophthalmol 29(3):261–266. https://doi.org/10.1097/ICU.0000000000000465CrossRefPubMed

10.

Baim AD, Movahedan A, Farooq AV, Skondra D (2019) The microbiome and ophthalmic disease. Exp Biol Med (Maywood) 244(6):419–429. https://doi.org/10.1177/1535370218813616CrossRef

11.

Cavuoto KM, Banerjee S, Galor A (2019) Relationship between the microbiome and ocular health. Ocul Surf 17(3):384–392. https://doi.org/10.1016/j.jtos.2019.05.006CrossRefPubMed

12.

Lin P (2019) Importance of the intestinal microbiota in ocular inflammatory diseases: a review. Clin Exp Ophthalmol 47(3):418–422. https://doi.org/10.1111/ceo.13493CrossRefPubMed

13.

Sansotta N, Peroni DG, Romano S, Rugiano A, Vuilleumier P, Baviera G, Italian Society of Pediatric Allergy, Immunology (SIAIP), Microbiota Committee, Italy (2019) The good bugs: the use of probiotics in pediatrics. Curr Opin Pediatr 31(5):661–669. https://doi.org/10.1097/MOP.0000000000000808CrossRefPubMed

14.

Sklar BA, Gervasio KA, Leng S, Ghosh A, Chari A, Wu AY (2019) Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series. BMC Ophthalmol 19(1):110. https://doi.org/10.1186/s12886-019-1118-xCrossRefPubMedPubMedCentral

15.

Nemet AY, Vinker S, Kaiserman I (2011) Associated morbidity of chalazia. Cornea. 30(12):1376–1381. https://doi.org/10.1097/ICO.0b013e31821de36fCrossRefPubMed

16.

Yam JC, Tang BS, Chan TM, Cheng AC (2014) Ocular demodicidosis as a risk factor of adult recurrent chalazion. Eur J Ophthalmol 24(2):159–163. https://doi.org/10.5301/ejo.5000341CrossRefPubMed

17.

Bonifazi E (2005) Linear chalaziosis. Eur J Pediatr Dermatol 15(3):183

18.

Burkhart CG, Burkhart CN (2008) Similar to acne vulgaris, bacteria may produce the biological glue that causes plugging of the meibomian gland leading to chalazions. Clin Exp Ophthalmol 36(3):295. https://doi.org/10.1111/j.1442-9071.2008.01714.xCrossRefPubMed

19.

Malekahmadi M, Farrahi F, Tajdini A (2017) Serum vitamin a levels in patients with chalazion. Med Hypothesis Discov Innov Ophthalmol 6(3):63–66PubMedPubMedCentral

20.

Lu LJ, Liu J (2016) Human microbiota and ophthalmic disease. Yale J Biol Med 89(3):325–330PubMedPubMedCentral

21.

Giacomin AL (2016) Infective and inflammatory eyelid disorders: conventional and unconventional therapies to maintain eye health and avoid lid surgery. EC Ophthalmology 3(6):435–445

22.

Weimer K, Gulewitsch MD, Schlarb AA, Schwille-Kiuntke J, Klosterhalfen S, Enck P (2013) Placebo effects in children: a review. Pediatr Res 74(1):96–102. https://doi.org/10.1038/pr.2013.66CrossRefPubMed

23.

Petersen C, Round JL (2014) Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol 16:1024–1033. https://doi.org/10.1111/cmi.12308CrossRefPubMedPubMedCentral

24.

Forbes JD, Chen CY, Knox NC, Marrie RA, El-Gabalawy H, de Kievit T, Alfa M, Bernstein CN, Van Domselaar G (2018) A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist? Microbiome. 6(1):221. https://doi.org/10.1186/s40168-018-0603-4CrossRefPubMedPubMedCentral

25.

Iovieno A, Lambiase A, Micera A, Stampachiacchiere B, Sgrulletta R, Bonini S (2009) In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis. Eur J Ophthalmol 19(5):708–716. https://doi.org/10.1177/112067210901900504CrossRefPubMed

26.

Geerling G, Tauber J, Baudouin C, Goto E, Matsumoto Y, O'Brien T, Rolando M, Tsubota K, Nichols KK (2011) The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 52(4):2050–2064. https://doi.org/10.1167/iovs.10-6997gCrossRefPubMedPubMedCentral

27.

Trujillo-Vargas CM, Schaefer L, Alam J, Pflugfelder SC, Britton RA, de Paiva CS (2019) The gut –eye-lacrimal gland-micobiome axis in Sjogren syndrome. Ocul Surf S1542-0124(19):30348–30349. https://doi.org/10.1016/j.jtos.2019.10.006CrossRef

28.

Kugadas A, Wright Q, Geddes-McAlister J, Gadjeva M (2017) Role of microbiota in strengthening ocular mucosal barrier function through secretory IgA. Invest Ophthalmol Vis Sci 58(11):4593–4600. https://doi.org/10.1167/iovs.17-22119CrossRefPubMedPubMedCentral

29.

Rizk M, Tuzmen S (2020) MicroRNAs and microbiota: is there a cross talk? Drugs Today 56(3):211–226. https://doi.org/10.1358/dot.2020.56.3.3079409CrossRef

30.

Nayyar A, Gindina S, Barron A, Hu Y, Danias J (2020) Do epigenetic changes caused by commensal microbiota contribute to development of ocular disease? A review of evidence. Hum Genomics 14:11. https://doi.org/10.1186/s40246-020-00257-5CrossRefPubMedPubMedCentral

31.

Verhagen FH, Bekker CPJ, Rossato M, Hiddingh S, de Vries L, Devaprasad A, Pandit A, Ossewaarde-van Norel J, ten Dam N, Moret-Pot MCA, Imhof SM, de Boer JH, Radstake TRDJ, Kuiper JJW (2018) A disease-associated microRNA cluster links inflammatory pathways and an altered composition of leukocyte subsets to noninfectious uveitis. Invest Ophthalmol Vis Sci 59(2):878–888. https://doi.org/10.1167/iovs.17-23643CrossRefPubMed

32.

Alvarez-Olmos MI, Oberhelman RA (2001) Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. Clin Infect Dis 32:1567–1576. https://doi.org/10.1086/320518CrossRefPubMed

33.

Rusu E, Enache G, Cursaru R et al (2019) Prebiotics and probiotics in atopic dermatitis. Exp Ther Med 18(2):926–931. https://doi.org/10.3892/etm.2019.7678CrossRefPubMedPubMedCentral

34.

Thomas DW, Greer FR, Committee on Nutrition; Section on Gastroenterology, Hepatology, and Nutrition (2010) Clinical report—probiotics and prebiotics in pediatrics. Pediatrics 126:1217–1231. https://doi.org/10.1542/peds.2010-2548CrossRefPubMed

35.

Dong Q, Brulc JM, Iovieno A, Bates B, Garoutte A, Miller D, Revanna KV, Gao X, Antonopoulos DA, Slepak VZ, Shestopalov VI (2011) Diversity of bacteria at healthy human conjunctiva. Invest Ophthalmol Vis Sci 52(8):5408–5413. https://doi.org/10.1167/iovs.10-6939CrossRefPubMedPubMedCentral

36.

Cavuoto KM, Mendez R, Miller D, Galor A, Banerjee S (2018) Effect of clinical parameters on the ocular surface microbiome in children and adults. Clin Ophthalmol 12:1189–1197. https://doi.org/10.2147/OPTH.S166547CrossRefPubMedPubMedCentral

37.

Cavuoto KM, Banerjee S, Miller D, Galor A (2018) Composition and comparison of the ocular surface microbiome in infants and older children. Transl Vis Sci Technol 7(6):16. https://doi.org/10.1167/tvst.7.6.16CrossRefPubMedPubMedCentral

38.

Ozkan J, Nielsen S, Diez-Vives C, Coroneo M, Thomas T, Willcox M (2017) Temporal stability and composition of the ocular surface microbiome. Sci Rep 7(1):9880. https://doi.org/10.1038/s41598-017-10494-9CrossRefPubMedPubMedCentral

39.

Kugadas A, Gadjeva M (2016) Impact of microbiome on ocular health. Ocul Surf 3:342–349. https://doi.org/10.1016/j.jtos.2016.04.004CrossRef

Title: Intestinal microbiome: a new target for chalaziosis treatment in children?
Authors: Mariaelena Filippelli
Roberto dell’Omo
Angela Amoruso
Ilaria Paiano
Marco Pane
Pasquale Napolitano
Silvia Bartollino
Ciro Costagliola
Publication date: 01-04-2021
Publisher: Springer Berlin Heidelberg
Keyword: Probiotics
Published in: European Journal of Pediatrics / Issue 4/2021
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-020-03880-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Intestinal microbiome: a new target for chalaziosis treatment in children?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

How to improve precision and reliability of diaphragm ultrasonographic measurements in newborns

Shivering has little diagnostic value in diagnosing serious bacterial infection in children: a systematic review and meta-analysis

Acute viral bronchiolitis as a cause of pediatric acute respiratory distress syndrome

Are biopsies always necessary in upper and lower gastrointestinal endoscopy in children? A retrospective 10-year analysis

Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units

Perinatal COVID-19: review of current evidence and practical approach towards prevention and management